You are here: Industry Insights > Market News > US company claims Irish firm Amgen infringing cancer drug patent

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Riociguat(625115-55-1)

Methyl [4,6-diaMino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyriMidin-5-yl]carbaMate

2-[1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyriMidine-4,5,6-triaMine(428854-24-4)

4,6-PyriMidinediaMine, 2-[1-[(2-fluorophenyl)Methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(phenylazo)-

1H-Pyrazolo[3,4-b]pyridine-3-carboximidamide, 1-[(2-fluorophenyl)methyl]-, hydrochloride (1:1)

1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboximidamide(256376-68-8)

US company claims Irish firm Amgen infringing cancer drug patent

firstwordpharmaMarch 12, 2019

Tag: Roche , Irish firm , cancer drug patent

Favorites

Roche's Genentech unit has filed a lawsuit in the US accusing Amgen of infringing a patent covering the cancer drug Avastin, Irish Examiner reported Monday.
Genentech said it has received a notice from the FDA that Amgen plans to launch its biosimilar, named Mvasi, in Ireland.
In seeking an injunction, Genentech argued that it will suffer substantial damage if Amgen is permitted to launch its therapy.
Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.

Previous:Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Next:Oncoceutics licenses rights for its anti-cancer compound to Ohara

SCG Cell Therapy partners A*STAR to accelerate RNA-based therapeutic development in Singapore

PRNewswireDecember 23, 2024

SCG Cell Therapy Pte Ltd (SCG),announced the signing of a Memorandum of Understanding (MoU) with A*STAR BTI and NATi to advance RNA-based therapeutics manufacturing process development and clinical translation.

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

US company claims Irish firm Amgen infringing cancer drug patent | Pharmasources.com

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

You may like
More>>

Electrochemical Polishing Equipment of Inner Stainless Steel Pipe

Specialty & agrochemical, pharma, Fertilizers and Biological Vacuum Belt Dryer Machine

Electrochemical aluminum cover Oral liquid aluminum cover Twisted anti-theft aluminum cover

Electrochemical Passivating Reagent for Stainless Steel

Electrochemical Polishing, Cleaning and Drying Equipment for Vacuum Insulation Cup Of Stainless Stee

Electrochemical Polishing Reagent for Nitinol

Chromium-free Electrochemical Polishing Reagent for Nickel Alloy

Electrochemical-Mechanical Abrasive Polishing Equipment

Agrochemicals biocatalysts

Agrochemical Intermediates Fluxametamide for Kill Insecticide CAS 928783-29-3

US company claims Irish firm Amgen infringing cancer drug patent

Related News

SCG Cell Therapy partners A*STAR to accelerate RNA-based therapeutic development in Singapore

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

You may likeMore>>

You may like
More>>